Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Kallyope closes $66mm Series B

Executive Summary

Kallyope Inc. (therapies involving the gut-brain axis) raised $66mm in its Series B financing from returning shareholders Lux Capital, Column Group, Polaris Partners, Illumina Ventures, and Alexandria Venture Investments, and new backers Euclidean Capital and Two Sigma Ventures. The company has early-stage programs aimed at modulation of gut-brain circuits. Kallyope will initially focus on therapies for metabolic, gastrointestinal, and neurological diseases.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies